SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

09 Nov 2023 Evaluate
The company witnessed a 22.90% growth in the revenue at Rs. 2148.74 millions for the quarter ended September 2023 as compared to Rs. 1748.35 millions during the year-ago period.A humble growth in net profit of 14.83% reported in the quarter ended September 2023 to Rs. 232.10  millions from Rs. 202.12 millions.Operating Profit saw a handsome growth to 397.04 millions from 334.31 millions in the quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 2148.74 1748.35 22.90 4098.94 3401.11 20.52 6906.21 7791.56 -11.36
Other Income 3.34 8.18 -59.17 12.15 11.93 1.84 25.74 31.04 -17.07
PBIDT 397.04 334.31 18.76 760.63 669.85 13.55 1372.25 1511.34 -9.20
Interest 44.61 16.06 177.77 85.34 25.14 239.46 82.23 53.66 53.24
PBDT 352.43 318.25 10.74 675.29 644.71 4.74 1290.02 1457.68 -11.50
Depreciation 42.97 45.64 -5.85 85.33 89.29 -4.43 222.81 189.29 17.71
PBT 309.46 272.61 13.52 589.96 555.42 6.22 1067.21 1268.39 -15.86
TAX 77.36 70.49 9.75 151.62 142.78 6.19 270.16 309.98 -12.85
Deferred Tax 23.63 -6.51 -462.98 32.89 -7.82 -520.59 -11.94 -11.52 3.65
PAT 232.10 202.12 14.83 438.34 412.64 6.23 797.05 958.41 -16.84
Equity 96.94 96.94 0.00 96.94 96.94 0.00 96.94 96.94 0.00
PBIDTM(%) 18.48 19.12 -3.37 18.56 19.70 -5.78 19.87 19.40 2.44

Gufic Biosciences Share Price

301.30 -1.35 (-0.45%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×